Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.76 +0.56 (+2.14%)
Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗
Berobenatide is one of the keys to Pfizer's future. 
Via The Motley Fool
Most active S&P500 stocks in Friday's session ↗
Via Chartmill
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations
Animal health company Zoetis (NYSE:ZTS) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The comp... 
Via StockStory
Pfizer (NYSE:PFE) Beats Q2 Expectations and Raises 2026 Revenue Guidance ↗
Via Chartmill
News headline image
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion.... 
Via StockStory
News headline image
3 Beaten-Down Stocks to Hold for the Next 10 Years ↗
Don't let their recent poor performances chase you away. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Q2 Earnings Call Highlights ↗
Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue... 
Via MarketBeat
Topics Earnings Intellectual Property
S&P 500 Prints Fresh Record As Chips Rip And Hormuz Talks Crack The Oil Trade ↗
Via Chartmill
Topics Stocks
News headline image
PFE Q2 Deep Dive: New Products Offset COVID Decline, R&D Pipeline Expands
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15... 
Via StockStory
Topics Artificial Intelligence
Looking for the most active stocks in the S&P500 index on Tuesday? ↗
Via Chartmill
News headline image
Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide on Weight Loss ↗
Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways. 
Via Benzinga
News headline image
BioNTech Q2 Earnings Call Highlights ↗
BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year... 
Via MarketBeat
Topics Earnings
News headline image
Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings ↗
Dow rises 1.35% with technology sector leading market gains. Pfizer beats Q2 earnings expectations. Oil down 4.2%, gold up 0.8%, European markets higher. 
Via Benzinga
Topics Stocks
News headline image
Pfizer Hikes 2026 Sales Outlook By $500 Million On Second-Quarter Beat ↗
Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost. 
Via Investor's Business Daily
News headline image
Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15... 
Via StockStory
News headline image
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Caterpillar, Pfizer and 3 Stocks to Watch Heading Into Tuesday ↗
Stocks to watch today: Caterpillar, Palantir, McDonald's, Snap, Pfizer. Positive Q2 earnings reported and upbeat sales guidance issued. 
Via Benzinga
News headline image
Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗
Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenue at $14.39B. Stock rose 0.1% on Monday. 
Via Benzinga
News headline image
SpaceX Could Swing $204 Billion After Earnings ↗
Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences. 
Via Benzinga
News headline image
Pfizer's Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield? ↗
The stock's yield is more than six times the S&P 500 average. 
Via The Motley Fool
Topics Stocks
News headline image
Pfizer (PFE) Q2 Earnings: What To Expect
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here’s what to expect. Pfizer beat analysts’ rev... 
Via StockStory
News headline image
Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That ↗
Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock? ↗
There is more to this stock than meets the eye. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Regeneron Pharmaceuticals Q2 Earnings Call Highlights ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP... 
Via MarketBeat
Topics ETFs Earnings
News headline image
Regency Centers Q2 Earnings Call Highlights ↗
Regency Centers (NASDAQ:REG) reported second-quarter operating momentum marked by higher occupancy, rent growth and an expanded development pipeline, prompting the grocery-anchored shopping center... 
Via MarketBeat
Topics ETFs Earnings
News headline image
Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials ↗
Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings. 
Via Benzinga
News headline image
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
From Pfizer Inc.
Via Business Wire
News headline image
What Health Experts Want You to Know About Pneumococcal Pneumonia
Via StatePoint Media
News headline image
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.